Mosapride as a Pre-Endoscopy Preparation in a Patient Receiving GLP-1 Receptor Agonist Therapy.

We present the case of a 66-year-old man who underwent upper gastrointestinal (GI) endoscopy and developed significant gastric residue after treatment with a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) for type 2 diabetes. Despite prolonged fasting, large volumes of gastric residue persisted, thus impairing mucosal visualization. Instead of discontinuing GLP-1RA therapy, mosapride citrate was introduced as a gastroprokinetic agent. Three days before endoscopy, the patient received mosapride, which resulted in complete gastric clearance and optimal endoscopic visualization. This case suggests that mosapride may be an effective pre-endoscopic preparation to counteract GLP-1RA-induced delayed gastric emptying.